Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251095 · ClinicalTrials.gov registry record · Phase 3
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
A Phase 3 study, sponsored by Achieve Life Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 821
- Enrollment target
NCT00251095 is a Phase 3 study that was terminated before completion, run by Achieve Life Sciences. The registered enrollment target is 821 participants.
The verdict
NCT00251095, a Phase 3 study, was terminated before completion, sponsored by Achieve Life Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 821 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.
Interventions
- DRUG Taxol
- DRUG TOCOSOL Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 821 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251095
The ClinicalTrials.gov registry entry for NCT00251095 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 821 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Taxol is the first listed.
NCT00251095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251095 about?
NCT00251095 is a clinical study titled "Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer". The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCO...
What is the current status of trial NCT00251095?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 821 participants. The study started on 2005-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00251095?
The interventions under investigation include: Taxol (DRUG), TOCOSOL Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00251095?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.